41
Participants
Start Date
December 7, 2020
Primary Completion Date
November 26, 2024
Study Completion Date
May 27, 2025
Ravulizumab
Weight-based doses of ravulizumab will be administered intravenously as a loading dose regimen followed by maintenance dosing every 4 or 8 weeks, depending upon weight.
Best Supportive Care
Participants will receive medications, therapies, and interventions per standard hospital treatment protocols (unless specifically prohibited by the protocol).
Research Site, Seoul
Research Site, Esplugues de Llobregat
Research Site, Madrid
Research Site, Atlanta
Research Site, Salamanca
Research Site, Madison
Research Site, Chicago
Research Site, Dallas
Research Site, Aurora
Research Site, Salt Lake City
Research Site, Tucson
Research Site, Haifa
Research Site, Jerusalem
Research Site, Portland
Research Site, Petah Tikva
Research Site, Ramat Gan
Research Site, Roma
Research Site, Fukushima
Research Site, Kobe
Research Site, Nagoya
Research Site, Osaka
Research Site, Seoul
Research Site, Barcelona
Research Site, Birmingham
Research Site, Bristol
Research Site, Newcastle upon Tyne
Lead Sponsor
Alexion Pharmaceuticals, Inc.
INDUSTRY